InMode (INMD) Scheduled to Post Earnings on Thursday

InMode (NASDAQ:INMD - Get Free Report) is set to announce its earnings results before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of $0.40 per share for the quarter. InMode has set its FY24 guidance at $2.53-2.57 EPS.Investors interested in listening to the company's conference call can do so using this link.

InMode (NASDAQ:INMD - Get Free Report) last issued its quarterly earnings data on Tuesday, February 13th. The healthcare company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.05. InMode had a return on equity of 29.80% and a net margin of 40.22%. The business had revenue of $126.80 million for the quarter, compared to analysts' expectations of $124.77 million. During the same period last year, the business earned $0.69 EPS. The business's revenue was down 5.1% on a year-over-year basis. On average, analysts expect InMode to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

InMode Stock Down 2.0 %

NASDAQ:INMD traded down $0.34 during trading hours on Thursday, hitting $17.02. 1,029,031 shares of the company traded hands, compared to its average volume of 1,574,299. The firm's 50-day simple moving average is $20.57 and its 200-day simple moving average is $21.69. InMode has a one year low of $16.82 and a one year high of $48.25. The company has a market cap of $1.43 billion, a PE ratio of 7.55 and a beta of 2.16.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on INMD shares. Needham & Company LLC restated a "hold" rating on shares of InMode in a research note on Tuesday, April 9th. UBS Group raised their target price on InMode from $24.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, February 14th. Finally, Barclays decreased their target price on InMode from $34.00 to $33.00 and set an "overweight" rating for the company in a research report on Friday, April 12th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $32.80.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.